Literature DB >> 23925980

Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population.

Katherine P Liao1, Tianxi Cai, Vivian S Gainer, Andrew Cagan, Shawn N Murphy, Chihchin Liu, Susanne Churchill, Stanley Y Shaw, Isaac Kohane, Daniel H Solomon, Robert M Plenge, Elizabeth W Karlson.   

Abstract

OBJECTIVE: Differences in lipid levels associated with cardiovascular (CV) risk between rheumatoid arthritis (RA) patients and the general population remain unclear. Determining these differences is important in understanding the role of lipids in CV risk in RA.
METHODS: We studied 2,005 RA subjects from 2 large academic medical centers. We extracted electronic medical record data on the first low-density lipoprotein (LDL) measurement, and total cholesterol and high-density lipoprotein (HDL) measurements within 1 year of the LDL measurement. Subjects with an electronic statin prescription prior to the first LDL measurement were excluded. We compared lipid levels in RA patients to recently published levels from the general US population using the t-test and stratifying by published parameters, i.e., 2007-2010, and women. We determined lipid trends using separate linear regression models for total cholesterol, LDL cholesterol, and HDL cholesterol, testing the association between year of measurement (1989-2010) and lipid level, adjusted by age and sex. Lipid trends in RA were qualitatively compared to the published general population trends.
RESULTS: Women with RA had a significantly lower total cholesterol (186 versus 200 mg/dl; P = 0.002) and LDL cholesterol (105 versus 118 mg/dl; P = 0.001) compared to the general population (2007-2010). HDL cholesterol was not significantly different in the 2 groups. In the RA cohort, total cholesterol and LDL cholesterol significantly decreased each year, while HDL cholesterol increased (all with P < 0.0001), consistent with overall trends observed in a previous study.
CONCLUSION: RA patients appear to have an overall lower total cholesterol and LDL cholesterol than the general population despite the general overall risk of CV disease in RA from observational studies.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925980      PMCID: PMC4060244          DOI: 10.1002/acr.22091

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  15 in total

1.  Revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett
Journal:  Bull Rheum Dis       Date:  1989

2.  Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis.

Authors:  Inmaculada del Rincón; Gregory L Freeman; Roy W Haas; Daniel H O'Leary; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2005-11

3.  Fasting time and lipid levels in a community-based population: a cross-sectional study.

Authors:  Davinder Sidhu; Christopher Naugler
Journal:  Arch Intern Med       Date:  2012-12-10

4.  Electronic medical records for discovery research in rheumatoid arthritis.

Authors:  Katherine P Liao; Tianxi Cai; Vivian Gainer; Sergey Goryachev; Qing Zeng-treitler; Soumya Raychaudhuri; Peter Szolovits; Susanne Churchill; Shawn Murphy; Isaac Kohane; Elizabeth W Karlson; Robert M Plenge
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

5.  Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis.

Authors:  V P van Halm; M M J Nielen; M T Nurmohamed; D van Schaardenburg; H W Reesink; A E Voskuyl; J W R Twisk; R J van de Stadt; M H M T de Koning; M R Habibuw; I E van der Horst-Bruinsma; B A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2006-06-07       Impact factor: 19.103

6.  Total cholesterol and LDL levels decrease before rheumatoid arthritis.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2009-10-23       Impact factor: 19.103

7.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  J Antonio Aviña-Zubieta; Hyon K Choi; Mohsen Sadatsafavi; Mahyar Etminan; John M Esdaile; Diane Lacaille
Journal:  Arthritis Rheum       Date:  2008-12-15

8.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Authors:  A Gonzalez; H Maradit Kremers; C S Crowson; K V Ballman; V L Roger; S J Jacobsen; W M O'Fallon; S E Gabriel
Journal:  Ann Rheum Dis       Date:  2007-05-21       Impact factor: 19.103

9.  Dyslipoproteinemia in the course of active rheumatoid arthritis.

Authors:  M B Lazarevic; J Vitic; V Mladenovic; B L Myones; J L Skosey; W I Swedler
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

10.  Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.

Authors:  Sherine E Gabriel; Cynthia S Crowson; Hilal Maradit Kremers; Michele F Doran; Carl Turesson; W Michael O'Fallon; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-01
View more
  31 in total

Review 1.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 2.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

3.  Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Xiaoqing Fu; Katherine Liao; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; Yuqing Zhang; Hyon Choi; John H Stone
Journal:  Arthritis Rheumatol       Date:  2019-09-16       Impact factor: 10.995

4.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

Review 5.  Managing premature atherosclerosis in patients with chronic inflammatory diseases.

Authors:  Alexandra Legge; John G Hanly
Journal:  CMAJ       Date:  2018-04-09       Impact factor: 8.262

Review 6.  Lipids in RA: Is Less Not Necessarily More?

Authors:  Jorge Plutzky; Katherine P Liao
Journal:  Curr Rheumatol Rep       Date:  2018-02-21       Impact factor: 4.592

7.  Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study.

Authors:  Su H Chu; Jing Cui; Jeffrey A Sparks; Bing Lu; Sara K Tedeschi; Cameron B Speyer; LauraKay Moss; Marie L Feser; Lindsay B Kelmenson; Elizabeth A Mewshaw; Jess D Edison; Kevin D Deane; Clary Clish; Jessica Lasky-Su; Elizabeth W Karlson; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

8.  Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Authors:  Katherine P Liao; Jun Liu; Bing Lu; Daniel H Solomon; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

Review 9.  Cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Katherine P Liao
Journal:  Trends Cardiovasc Med       Date:  2016-08-03       Impact factor: 6.677

Review 10.  High-density lipoprotein function in rheumatoid arthritis.

Authors:  Michelle J Ormseth; C Michael Stein
Journal:  Curr Opin Lipidol       Date:  2016-02       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.